University of Texas Texas AM Investment Management Co. Purchases 70 Shares of Cencora, Inc. $COR

University of Texas Texas AM Investment Management Co. lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 50.0% in the second quarter, Holdings Channel.com reports. The fund owned 210 shares of the company’s stock after acquiring an additional 70 shares during the quarter. University of Texas Texas AM Investment Management Co.’s holdings in Cencora were worth $63,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Cencora by 8.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after purchasing an additional 787,858 shares during the last quarter. Wellington Management Group LLP raised its stake in Cencora by 7.2% during the first quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after buying an additional 363,402 shares during the last quarter. Boston Partners lifted its holdings in Cencora by 8.1% in the first quarter. Boston Partners now owns 5,411,193 shares of the company’s stock valued at $1,505,984,000 after buying an additional 404,093 shares during the period. Invesco Ltd. boosted its position in Cencora by 42.1% during the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after acquiring an additional 1,364,433 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Cencora by 9.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after acquiring an additional 154,311 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Performance

COR opened at $333.02 on Friday. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $334.34. The company has a market cap of $64.56 billion, a price-to-earnings ratio of 34.26, a PEG ratio of 1.55 and a beta of 0.63. The company’s fifty day moving average price is $304.09 and its two-hundred day moving average price is $295.02. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. During the same period in the previous year, the firm posted $3.34 earnings per share. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s payout ratio is currently 22.63%.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,544 shares of company stock valued at $12,230,941. Company insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the subject of several recent analyst reports. Morgan Stanley set a $330.00 target price on Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. Jefferies Financial Group raised their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Mizuho boosted their target price on shares of Cencora from $316.00 to $334.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Evercore ISI set a $340.00 target price on shares of Cencora in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and a consensus price target of $324.91.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.